




Cite this: *RSC Adv.*, 2023, 13, 27167

# Exploring the anti-obesity bioactive compounds of *Thymelaea hirsuta* and *Ziziphus spina-christi* through integration of lipase inhibition screening and molecular docking analysis†

Rokia M. Abdallah, Hala M. Hammada, Nahla S. El-Gazzar,  \* Reham S. Ibrahim  and Shaimaa M. Sallam

Activity-guided fractionation of the ethanolic extracts of *Thymelaea hirsuta* and *Ziziphus spina-christi* furnished eight compounds with pancreatic lipase inhibitory activity. Six compounds were isolated from the chloroform fraction of *T. hirsuta*. It is worth mentioning that this is the first report for the isolation of 5,7,4'-trihydroxy-8-methoxycarbonyl flavanol (2), daphnodorin G-3''-methyl ether (4) and daphnodorin G (5) from genus *Thymelaea*. Moreover, daphnoretin (1), neochamaejasmin A (3) and daphnodorin B (6) were also isolated from the chloroform fraction of the same plant. On the other hand, quercetin 3-O- $\alpha$ -L-rhamnopyranosyl-(1  $\rightarrow$  2)-[ $\alpha$ -L-rhamnopyranosyl-(1  $\rightarrow$  6)]- $\beta$ -D-galactopyranoside (7) and 3-O-[ $\alpha$ -L-fucopyranosyl-(1  $\rightarrow$  2)- $\beta$ -D-glucopyranosyl-(1  $\rightarrow$  3)- $\alpha$ -L-arabinopyranosyl] jujubogenin (christinin A) (8) were isolated from the *n*-butanol fraction of *Z. spina-christi*. Structure elucidation of the isolated compounds was carried out by detailed analysis of 1D and 2D spectral data. These compounds showed percentage inhibitions of 72% (1), 52% (2), 61.8% (3), 39% (4), 69.5% (5), 3.5% (6), 68% (7) and 75% (8) at the concentration of 250  $\mu$ M and XP-G scores of lipase inhibition were 11.40 (1), 8.71 (2), 6.13 (3), 8.23 (4), 6.22 (5), 9.76 (6), 14.66 (7) and 12.00 (8). This is the first report of the isolation of lipase inhibitors from both plants *T. hirsuta* and *Z. spina-christi*. In addition to that, this might result in presenting the biscoumarin, daphnoretin, and the dammarane saponin, christinin A, as potent lipase inhibitors.

Received 26th August 2023  
Accepted 4th September 2023

DOI: 10.1039/d3ra05826c

rsc.li/rsc-advances

## 1. Introduction

Obesity is a "New World Syndrome". It is considered as a risk factor for chronic diseases including, cardiovascular diseases, type 2 diabetes, hypertension, and stroke.<sup>1,2</sup>

Pancreatic lipase is the principal lipolytic enzyme synthesized and secreted by the pancreas which is responsible for digestion of 50–70% of dietary fats.<sup>3–5</sup> Reduction of the fat digestion and hence, the absorption of dietary lipids in the gastrointestinal tract through the inhibition of pancreatic lipase is an important approach for the treatment of obesity.<sup>5–9</sup>

Orlistat (a semi-synthetic hydrogenated derivative of lipstatin) is considered a potent inhibitor of lipase enzyme, as it inhibits the absorption of 30% of dietary fats.<sup>10,11</sup> It has been approved by the Food and Drug Administration as an effective treatment of human obesity.<sup>8,12</sup> However, orlistat showed some serious side effects like steatorrhea, fecal incontinence, flatulence, risks of vitamin deficiencies and liver diseases.<sup>13–15</sup> It is

contraindicated in pregnancy, patients with malabsorption disorders and reduced gallbladder function.<sup>16</sup> Consequently, there is a need to explore safer alternative and complementary therapies to combat obesity.<sup>17</sup>

Many researchers reported potentiation of phyto-compounds and their anti-lipase effect.<sup>18–21</sup> This has prompted us to investigate *Thymelaea hirsuta* and *Ziziphus spina-christi* for their lipase inhibitory activities.

*Thymelaea hirsuta* (L.), called "Al Methnan" (Thymelaeaceae). It is a small evergreen shrub which is native to the Mediterranean region. This genus has not been investigated extensively but it is characterized by the presence of flavonoids (luteolin, *trans*-tiliroside, chrysoeriol), terpenes (daphnane terpenes), sterols and coumarins (daphnoretin).<sup>22–24</sup> It is used traditionally for treatment of diabetes,<sup>25,26</sup> dermatitis, hair-fall, constipation and vermicide. Furthermore, the aerial parts were reported to be effective inhibitors of  $\alpha$ -glucosidase *in vivo*.<sup>27,28</sup>

On other hand, *Ziziphus spina-christi* (Rhamnaceae) is known in Egypt as 'Nabq' or 'Sidr',<sup>29</sup> it is a tropical tree with thorny branches and producing small, orange-yellow fruits. It is used in folk medicine for the treatment of diabetes mellitus. Many studies showed improved *in vitro* effect of *Z. spina-christi* extract on the activity of  $\alpha$ -amylase enzyme resulted in significant

Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. E-mail: Nahla.elgazzar@alexu.edu.eg; Shawky.nahla@yahoo.com

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ra05826c>



reduction in blood glucose level together with significant rise in serum insulin.<sup>30,31</sup> Literature survey of *Z. spina-christi* species revealed the presence of different types of saponins (betulinolaldehyde, betulin, christinin A),<sup>32–34</sup> flavonoids (quercetin, quercetin 3-O-[ $\beta$ -xylosyl-(1  $\rightarrow$  2)- $\alpha$ -rhamnoside]-4'-O- $\alpha$ -rhamnoside, quercetin 3-O- $\alpha$ -rhamnopyranosyl-(1  $\rightarrow$  6)- $\alpha$ -rhamnopyranosyl-(1  $\rightarrow$  2)- $\beta$ -galactopyranoside, quercetin-3-O- $\alpha$ -arabinosyl(1  $\rightarrow$  2)- $\alpha$ -rhamnoside, galocatechin<sup>32</sup> and phenolics (*p*-hydroxybenzoic)).

Molecular docking studies are among the computational techniques which provided information about the interaction between ligand and the protein binding site; leading to fast and efficient development of potent target modulators.<sup>35</sup> So that, *in silico* and *in vitro* studies will be conducted on isolates from the two selected Egyptian plants to evaluate their lipase inhibitory activity as well as prediction of their pharmacokinetic ADMET properties.

## 2. Materials and methods

### 2.1. General

Rotary evaporator: BUCHI Rotavapor R-200, was used for evaporation of solvents under reduced pressure. TLC analysis was conducted on silica gel plates (silica gel 60 F<sub>254</sub> with adsorbent layer thickness 0.25 mm plates, Merck, Darmstadt, Germany). TLC spots were located using a UV lamp and by heating after spraying with acidic anisaldehyde. Silica gel (Kieselgel 60, 0.063–0.20 mm, Merck, Darmstadt, Germany) and Sephadex LH-20 (Amersham Pharmacia Biotech AB) were used for column chromatography. 1D (<sup>1</sup>H and <sup>13</sup>C) and 2D NMR (HSQC, HMBC, NOESY, and COSY) spectra were recorded on Bruker DRX-400 MHz Ultrashield spectrometers (Bruker BioSpin, Billerica, MA, USA) in DMSO-d<sub>6</sub> or CD<sub>3</sub>OD solution. <sup>1</sup>H chemical shifts are referenced to the residual proton signal of the solvents ( $\delta$  2.49 or 3.30, respectively), while <sup>13</sup>C chemical shifts are expressed in reference to the solvent signals ( $\delta$  39.5 or 49.0, respectively). RP-MPLC was carried out with a BUCHI Pure C-815 Flash chromatograph apparatus attached with packed column, silica gel 100 C<sub>18</sub> reversed phase, 0.04–0.063 mm column (250 mm  $\times$  20 mm i.d.) monitored with a UV detector (254 nm). UV absorptions of the *in vitro* assay were measured on a BioTek, 800 TS Microplate spectrophotometer. RADWAG® AS 220.R2 sensitive balance was used for weighing solid materials. JENWAY 3510 PH Meter was used for adjusting the buffer PH. Incubator BT 1500 (BTC, Egypt), was used for incubation at 37 °C. Pancreatic lipase (type II, 100–500 units per mg protein), *para* nitrophenyl palmitate (lipase substrate) were purchased from Sigma Chemicals (USA) and orlistat (a lipase inhibitor used as positive control for the *in vitro* lipase inhibitory assay) was obtained from European Egyptian Pharmaceuticals (Egypt).

### 2.2. Plant material

Both plants *Ziziphus spina christi* (aerial parts) and *Thymelaea hirsuta* (roots) were collected from the Egyptian Siwa desserts and Ras El Hikma desserts, Matrouh, respectively, in March 2018. All plant were identified by Prof. Selim Heneidy at the

Herbarium, Faculty of Science, Alexandria University, Egypt. Voucher specimens (TH004 and TH007 for *Z. spina christi* and *T. hirsuta*, respectively) were deposited in the Pharmacognosy Department, Faculty of Pharmacy, Alexandria University, Egypt.

### 2.3. Extraction and isolation

Aerial parts of *Z. spina-christi* and roots of *T. hirsuta* (350 g of each plant) were dried, ground, extracted by percolation at room temperature with 90% ethanol until exhaustion. The solvent was evaporated under reduced pressure yielding a solid residue. Also, dried roots of *T. hirsuta* (1.7 kg) were extracted with 70% ethanol, filtered and concentrated. The alcoholic extract of *Z. spina christi* and *T. hirsuta* subjected to pancreatic lipase inhibition assay. Then, each residue was suspended in ethanol: water 1:1 v/v and partitioned with organic solvents of increasing polarities. Four fractions; light petroleum, chloroform, ethyl acetate and *n*-butanol were subjected to pancreatic lipase inhibition assay. The most bioactive fractions were the chloroform fraction and *n*-butanol fraction of *Z. spina-christi* and roots of *T. hirsuta*, respectively. The chloroform fraction was chromatographed using normal silica gel column and purified repeatedly with sephadex LH columns and crystallization was performed to afford six compounds (1–6) (Fig. 1). Compounds 1–6 were identified as daphnoretin (1), 5,7,4'-trihydroxy-8-methoxycarbonyl flavanol (2),<sup>36</sup> neochamaejasmin A (3),<sup>37</sup> daphnodorin G-3''-methyl ether (4), daphnodorin G (5),<sup>38</sup> daphnodorin B (6)<sup>39</sup> by detailed analysis of NMR data. It is worth mentioning that this is the first report for the isolation of the compounds (2), (4) and (5) from genus *Thymelaea*. On the other hand, the butanolic fraction was subjected to further purification of subfractions using column chromatography and crystallization was performed to afford two compounds (7–8) (Fig. 1). Compounds 7–8 were identified as quercetin 3-O- $\alpha$ -L-rhamnopyranosyl-(1  $\rightarrow$  2)-[ $\alpha$ -L-rhamnopyranosyl-(1  $\rightarrow$  6)]- $\beta$ -D-galactopyranoside (7)<sup>40</sup> and 3-O-[ $\alpha$ -L-fucopyranosyl-(1  $\rightarrow$  2)]- $\beta$ -D-glucopyranosyl-(1  $\rightarrow$  3)- $\alpha$ -L-arabinopyranosyl]jubilogenin (christinin A) (8)<sup>41</sup> by detailed analysis of NMR data and agreement of the spectral data to those reported in literature.

The detailed spectral analysis and experimental procedure for lipase inhibition assay are given as ESI.†

**5,7,4'-Trihydroxy-8-methoxycarbonyl flavanol (2).** White crystals, m.p. °C: 221–222° (MeOH), <sup>1</sup>H-NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 4.75 (1H, *d*, *J* = 6.7 Hz, H-2), 3.88 (1H, *m*, H-3), 2.60 (1H, *dd*, *J* = 16.2, 5.2 Hz, H-4), 2.41 (1H, *dd*, *J* = 16.2, 7.2 Hz, H-4), 6.00 (1H, *s*, H-6), 7.16 (2H, *d*, *J* = 8.3 Hz, H-2'), 6.74 (2H, *d*, *J* = 8.3 Hz, H-3'), 6.74 (2H, *d*, *J* = 8.3 Hz, H-5'), 7.16 (2H, *d*, *J* = 8.3 Hz, H-6'), 3.68 (3H, *s*, OCH<sub>3</sub>), 5.08 (1H, *br. s*, HO-3), 10.54 (1H, *s*, HO-5), 10.54 (1H, *s*, HO-7), 9.46 (1H, *s*, HO-4'); <sup>13</sup>C-NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 81.1 (C-2), 66.9 (C-3), 27.3 (C-4), 159.8 (C-5), 96.3 (C-6), 158.7 (C-7), 98.4 (C-8), 154.8 (C-9), 100.1 (C-10), 130.0 (C-1'), 128.1 (C-2'), 115.2 (C-3'), 157.1 (C-4'), 115.2 (C-5'), 128.1 (C-6'), 169.4 (C=O), 52.0 (OCH<sub>3</sub>).

**Daphnodorin G-3''-methyl ether (4).** Amorphous yellow powder, <sup>1</sup>H-NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 4.78 (1H, *d*, *J* = 6.4 Hz, H-2), 3.88 (*m*, H-3), 5.12 (1H, *d*, *J* = 4.6 Hz, HO-3), 2.56 (1H, *dd*, *J* = 5.1, 16.3 Hz, H-4), 2.46 (1H, *dd*, *J* = 7.0, 16.3 Hz, H-4), 6.29






Fig. 1 Structures of compounds 1–8.

(1H, s, H-6), 6.91 (2H, *d*, *J* = 8.8 Hz, H-2', 6'), 6.59 (2H, *d*, *J* = 8.8 Hz, H-3', 5'), 3.18 (3H, s, OCH<sub>3</sub>), 5.99 (1H, *d*, *J* = 2.2 Hz, H-6''), 5.80 (1H, *d*, *J* = 2.2 Hz, H-8''), 7.23 (2H, *d*, *J* = 8.8 Hz, H-2''', 6'''), 6.77 (2H, *d*, *J* = 8.8 Hz, H-3''', 5'''), 11.70 (1H, s, HO), 10.23 (1H, s, HO), 9.80 (1H, s, HO), 9.41 (1H, s, HO), 9.41 (1H, s, HO); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ: 80.4 (C-2), 65.7 (C-3), 27.3 (C-4), 100.7 (C-

4a), 159.6 (C-5), 91.8 (C-6), 160.1 (C-7), 102.5 (C-8), 153.4 (C-8a), 129.6 (C-1'), 127.5 (C-2', 6'), 115.3 (C-3', 5'), 157.1 (C-4'), 117.5 (C-2''), 85.0 (C-3''), 54.4 (OCH<sub>3</sub>), 193.1 (C-4''), 99.0 (C-4'a), 163.8 (C-5''), 96.7 (C-6''), 167.2 (C-7''), 94.9 (C-8''), 161.0 (C-8'a), 124.7 (C-1'''), 128.1 (C-2''', 6'''), 115.3 (C-3''', 5'''), 158.9 (C-4''').

**Daphnodorin G (5).** Amorphous yellow powder,  $^1\text{H-NMR}$  (400 MHz,  $\text{DMSO-}d_6$ )  $\delta$ : 4.71 (1H,  $d$ ,  $J = 6.9$  Hz, H-2), 3.76 ( $m$ , H-3), 5.07 (1H,  $d$ ,  $J = 5.1$  Hz, HO-3), 2.59 (1H,  $dd$ ,  $J = 5.2$ , 16.4 Hz, H-4), 2.43 (1H,  $dd$ ,  $J = 7.8$ , 16.4 Hz, H-4), 6.27 (1H,  $s$ , H-6), 6.93 (2H,  $d$ ,  $J = 8.2$  Hz, H-2', 6'), 6.62 (2H,  $d$ ,  $J = 8.2$  Hz, H-3', 5'), 6.22 (1H,  $s$ , 3''-HO), 5.98 (1H,  $d$ ,  $J = 2.2$  Hz, H-6''), 5.87 (1H,  $d$ ,  $J = 2.2$  Hz, H-8''), 7.22 (2H,  $d$ ,  $J = 8.5$  Hz, H-2''', 6'''), 6.76 (2H,  $d$ ,  $J = 8.5$  Hz, H-3''', 5'''), 11.77 (1H,  $s$ , HO), 10.01 (1H,  $s$ , HO), 9.74 (1H,  $s$ , HO), 9.38 (1H,  $s$ , HO), 9.38 (1H,  $s$ , HO);  $^{13}\text{C-NMR}$  (100 MHz,  $\text{DMSO-}d_6$ )  $\delta$ : 80.4 (C-2), 66.2 (C-3), 28.02 (C-4), 102.6 (C-4a), 158.8 (C-5), 91.5 (C-6), 159.5 (C-7), 106.4 (C-8), 151.8 (C-8a), 129.8 (C-1'), 127.8 (C-2', 6'), 115.0 (C-3', 5'), 157.0 (C-4'), 117.8 (C-2''), 80.9 (C-3''), 192.9 (C-4''), 98.8 (C-4''a), 163.8 (C-5''), 96.7 (C-6''), 167.4 (C-7''), 94.9 (C-8''), 161.4 (C-8''a), 124.7 (C-1'''), 128.6 (C-2''', 6'''), 115.1 (C-3''', 5'''), 158.7 (C-4''').

The detailed experimental procedure for lipase inhibition assay is given as ESI.†

#### 2.4. *In silico* docking study of the lipase inhibitory activity of isolated compounds (1–8)

The 3D geometry (X-ray crystal structure) of human pancreatic lipase complexed with the ligand; diundecyl phosphatidyl choline (PLC) was obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) (PDB code: 1LPA, resolution; 3.04 Å)<sup>42,43</sup> and prepared with the protein preparation wizard of Schrödinger Suite<sup>44</sup> where water molecules were deleted, protein was typed with OPLS3 force field and minimized. Next, a receptor grid was generated using the co-crystallized ligand as ref. 45.

All ligands (the isolated compounds from *T. hirsuta* and *Z. spina christi*) were obtained from NCBI Pubchem.<sup>46</sup> Ligands were optimized and energetically minimized through OPLS 3 force field algorithm embedded in the LigPrep module of Schrödinger Suite.<sup>47</sup> The ionization states within pH range  $7 \pm 2$  were generated.

In the docking experiment, Glide docking engine within the Schrödinger Suite was utilized.<sup>48,49</sup>

#### 2.5. *In silico* prediction of pharmacokinetic ADMET properties

After the step of molecular docking, ADMET and drug-like properties of the isolated compounds were evaluated using

Qikprop module embedded in Schrödinger® Suite software package. Qikprop was performed to assess the drug-like properties of all the isolates by calculation of the ADME (absorption, distribution, metabolism, and excretion) properties of the ligands.<sup>50</sup> Results of the pharmacokinetics study are demonstrated in Table S1 in the ESI.†

### 3. Results and discussion

The *in vitro* spectrophotometric 96-well lipase inhibitory assay described by Slanc<sup>4,51</sup> was used to evaluate the two selected Egyptian plants. Reaction mixtures containing 20  $\mu\text{l}$  of the enzyme solution, 50  $\mu\text{l}$  of the tested sample extract solution and 120  $\mu\text{l}$  of Tris-base buffer solution, were incubated at 37 °C for 25 min. Then 10  $\mu\text{l}$  of PNP substrate was added to the reaction mixture, followed by incubation at 37 °C for 30 min. Finally, the absorbance of released *p*-nitro phenol was measured at 405 nm using a microplate reader. The activity assay was performed in triplicate for each treatment and orlistat is used as a positive control. Percent inhibition values of the alcoholic plant extracts at concentration of (1 mg  $\text{ml}^{-1}$ ) were determined. It was observed that the alcoholic extracts of *Z. spina christi* and *T. hirsuta* showed significant lipase inhibitory activity with 93% and 70% inhibition values, respectively.

The results of the *in vitro* spectrophotometric 96-well lipase inhibitory assay of different fractions of the forementioned plants extracts were demonstrated in (Table 1). It was observed that the butanolic fraction of *Z. spina christi* showed the most significant anti-lipase activity (80% inhibition) followed by *T. hirsuta* chloroform fraction (61% inhibition). As a result, these two fractions from both plants were selected for further phytochemical investigation.

Six compounds were isolated and identified from *T. hirsute*, in addition to, two compounds were isolated from of *Z. spina christi* which were demonstrated in the schematic diagrams (Fig. S1 and S2,† respectively) present in the ESI.†

All these compounds were tested for their lipase inhibitory potencies following the Slanc method. Lipase inhibitors reduce the conversion of para nitro phenyl palmitate (PNPP) to its coloured metabolite *para*-nitro phenol, thus, the decrease in the absorbance produced was used as a criterion to assess lipase inhibition. The percentage inhibition was calculated for each inhibitor at the concentration of 0.25 mM.

**Table 1** Lipase inhibition by the fractions obtained from the *Thymelaea hirsuta* and *Ziziphus spina-christi* extracts expressed as % inhibition values

Plant name	Fraction	Percentage lipase inhibitory activity <sup>a</sup> (%)
<i>Thymelaea hirsuta</i> roots	Chloroform	61
	Light petrol	56
	Ethyl acetate	45
	<i>n</i> -Butanol	–27
<i>Ziziphus spina-christi</i> aerial parts	<i>n</i> -Butanol	80
	Light petrol	60
	Chloroform	58
	Ethyl acetate	–96

<sup>a</sup> Concentration at 1 mg  $\text{ml}^{-1}$ .





The results (Table 2) showed that christinin A (8) and daphnoretin (1) were ranked as the most active compounds possessing the highest % inhibition values of 75 and 72%, respectively. On the contrary, daphnodorin B was considered as the least active compound with an % inhibition value of 3.5%. Results also revealed that the tested compounds daphnodorin G, quercetin 3-*O*-(2,6-di-*O*- $\alpha$ -rhamnopyranosyl- $\beta$ -galactopyranoside), neochamaejasmin A, 5,7,4'-trihydroxy-8-methoxycarbonyl flavanol and daphnodorin G-3''-*O*-methyl ether exhibited inhibition of PL activity with % inhibition values are 69.5%, 68%, 61.8%, 52% and 39%, respectively. So, these compounds could be considered as potent lipase inhibitors or drug leads for further drug development. It was worthy to mention that this is the first report of these isolated compounds from the two plants: *T. hirsuta* and *Z. spina-christi* for lipase inhibition. Furthermore, the extracts are synergistically showing better lipase inhibition and this can be useful for ethno-pharmacological use of these plant species.

To investigate the mechanism of action and binding of compounds to active site of the lipase enzyme crystalline structure (1LPA), we conducted a molecular docking study using Glide docking engine within the Schrodinger molecular modeling suite<sup>35</sup> between the target (PDB code: 1LPA), ligands (orlistat and the isolated compounds from both *T. hirsuta* and *Z. spina-christi*), aiming to obtain a deep understanding to the compounds' binding modes inside the enzyme active site and the resulting complexes were scored in terms of GLIDE scores (XPG score). A greater negative numerical value of the docking G score indicates a stronger predicted binding of the ligand-

target complex. The docking protocol used flexible ligand sampling and standard precision with no docking constraints.

The molecular docking results shown in Fig. S3-S5† and Table 3, demonstrated that quercetin 3-*O*-(2,6-di-*O*- $\alpha$ -rhamnopyranosyl- $\beta$ -galactopyranoside) (7), christinin A (8) and daphnoretin (1) had the highest binding affinity (−14.66, −12.00 and −11.40 kcal mol<sup>−1</sup>, respectively) to the 1LPA, followed by daphnodorin B (6), orlistat (positive control), 5,7,4'-trihydroxy-8-methoxycarbonyl flavanol (2) and daphnodorin G-3''-methyl ether (4) (−9.76, −8.91, −8.71 and −8.23 kcal mol<sup>−1</sup>, respectively). On the other hand, daphnodorin G (5) and neochamaejasmin A (3) had the lowest binding energy (−6.22 and −6.13 kcal mol<sup>−1</sup>, respectively) compared to the others.

From the results of the pharmacokinetics study demonstrated in Table S1,† it was observed that all the compounds' properties lied within the acceptable range of human use. However, some of the pharmacokinetic ADMET properties – especially those depending on solubility – of both the saponin (christinin A) and the flavonoid glycoside (quercetin 3-*O*-(2,6-di-*O*- $\alpha$ -rhamnopyranosyl- $\beta$ -galactopyranoside)) lied outside the acceptable range of human use, therefore, further *in vitro* pharmacokinetic experiments are recommended to verify the predicted *in silico* results and to afford better understanding on their ADMET profiles.

The isolated natural compounds were found to possess the best drug-like properties by Lipinski's rule of five shown in Table S1 in the ESI.† The drug molecules which have low, mol. wt. are transported, diffused and absorbed without difficulty in comparison to large molecules.<sup>52,53</sup> Furthermore, all

**Table 2** Lipase inhibition of the isolated compounds (1–8) expressed as % inhibition at concentration of 0.25 mM<sup>a</sup>

Compound name	% Inhibition
Christinin A (8)	75
Daphnoretin (1)	72
Daphnodorin G (5)	69.5
Quercetin 3- <i>O</i> -(2,6-di- <i>O</i> - $\alpha$ -rhamnopyranosyl- $\beta$ -galactopyranoside) (7)	68
Neochamaejasmin A (3)	61.8
5,7,4'-Trihydroxy-8-methoxycarbonyl flavanol (2)	52
Daphnodorin G-3''-methyl ether (4)	39
Daphnodorin B (6)	3.5

<sup>a</sup> IC<sub>50</sub> of orlistat (positive control) = 0.0627 mM.

**Table 3** Lipase inhibition of the tested compounds along with orlistat expressed as XP-G scores

Compound name	Docking XPG score (kcal mol <sup>−1</sup> )
Quercetin 3- <i>O</i> -(2,6-di- <i>O</i> - $\alpha$ -rhamnopyranosyl- $\beta$ -galactopyranoside) (7)	−14.66
Christinin A (8)	−12.00
Daphnoretin (1)	−11.40
Daphnodorin B (6)	−9.76
Orlistat (positive control)	−8.91
5,7,4'-Trihydroxy-8-methoxycarbonyl flavanol (2)	−8.71
Daphnodorin G-3''-methyl ether (4)	−8.23
Daphnodorin G (5)	−6.22
Neochamaejasmin A (3)	−6.13



the isolates are showing activity against lipase and not on the nervous system.

## 4. Conclusion

In conclusion, the results of the present study clearly demonstrated that the two compounds; christinin A (8) and daphnoretin (1) have excellent binding interactions with lipase enzyme compared to the standard. These might corporate in presenting the biscoumarin; daphnoretin and the dammarane saponin; christinin A as potent lipase inhibitors which have not been previously reported for this activity.

## Author contributions

Rokia M. Abdallah: supervision and conceptualization. Hala M. Hammada: supervision, original draft preparation, reviewing and editing. Nahla S. El-Gazzar: methodology, writing, visualization, editing and investigation. Reham S. Ibrahim: supervision and software. Shaimaa M. Sallam: supervision and validation.

## Conflicts of interest

There are no conflicts to declare.

## References

- 1 G. A. Bray, *J. Nutr.*, 2002, **132**, 3451S–3455S.
- 2 P. G. Kopelman, *Nature*, 2000, **404**, 635–643.
- 3 M. E. Lowet, *J. Lipid Res.*, 2002, **43**, 2007–2016.
- 4 R. Birari, S. K. Roy, A. Singh and K. K. Bhutani, *Nat. Prod. Commun.*, 2009, **4**, 1089–1092.
- 5 H. Abdul Rahman, N. Saari, F. Abas, A. Ismail, M. W. Mumtaz and A. Abdul Hamid, *Int. J. Food Prop.*, 2017, **20**, 2616–2629.
- 6 R. Chakrabarti, *Expert Opin. Ther. Targets*, 2009, **13**, 195–207.
- 7 S. Hasani-Ranjbar, Z. Jouyandeh and M. Abdollahi, *J. Diabetes Metab. Disord.*, 2013, **12**, 1–10.
- 8 M. Mukherjee, *J. Mol. Catal. B: Enzym.*, 2003, **22**, 369–376.
- 9 C. Roh and U. Jung, *Int. J. Mol. Sci.*, 2012, **13**, 1710–1719.
- 10 W. Chanmee, C. Chaicharoenpong and A. Petsom, *Food Nutr. Sci.*, 2013, **04**, 554–558.
- 11 S. Henness and C. M. Perry, *Drugs*, 2006, **66**, 1625–1656.
- 12 D. Isler, C. Moeglen, N. Gains and M. K. Meier, *Br. J. Nutr.*, 1995, **73**, 851–862.
- 13 R. B. Birari and K. K. Bhutani, *Drug Discovery Today*, 2007, **12**, 879–889.
- 14 J. G. Kang and C. Y. Park, *Diabetes & Metabolism Journal*, 2012, **36**, 13–25.
- 15 D. S. Weigle, *J. Clin. Endocrinol. Metab.*, 2003, **88**, 2462–2469.
- 16 T. D. Filippatos, C. S. Derdemezis, I. F. Gazi, E. S. Nakou, D. P. Mikhailidis and M. S. Elisaf, *Drug Saf.*, 2008, **31**, 53–65.
- 17 R. B. Birari and K. K. Bhutani, *Drug Discovery Today*, 2007, **12**.
- 18 H. Fei, M. Li, W. Liu, L. Sun, N. Li, L. Cao, Z. Meng, W. Huang, G. Ding, Z. Wang and W. Xiao, *Pharm. Biol.*, 2016, **54**, 2845–2850.
- 19 N. Jaradat, A. N. Zaid and E. Z. Zaghal, *Marmara Pharm. J.*, 2017, **21**, 828–863.
- 20 A. I. Martinez-Gonzalez, E. Alvarez-Parrilla, Á. G. Díaz-Sánchez, L. A. de la Rosa, J. A. Núñez-Gastélum, A. A. Vazquez-Flores and G. A. Gonzalez-Aguilar, *Food Technol. Biotechnol.*, 2017, **55**, 519–530.
- 21 P. Worsztynowicz, M. Napierała, W. Białas, W. Grajek and M. Olkowicz, *Process Biochem.*, 2014, **49**, 1457–1463.
- 22 N. O. Amari, M. Bouzouina, A. Berkani and B. Lotmani, *Asian Pac. J. Trop. Dis.*, 2014, **4**, 104–109.
- 23 T. Mekhelfi, K. Kerbab, G. Guella, L. Zaiter, S. Benayache and F. Benayache, *Pharm. Lett.*, 2014, **6**, 152–156.
- 24 A. M. Rizk and H. Rimpler, *Phytochemistry*, 1972, **11**, 473–475.
- 25 A. Ziyat, A. Legssyer, H. Mekhfi, A. Dassouli, M. Serhrouchni and W. Benjelloun, *J. Ethnopharmacol.*, 1997, **58**, 45–54.
- 26 M. Bnouham, F. Z. Merhfour, A. Legssyer, H. Mekhfi, S. Maâllem and A. Ziyat, *Pharmazie*, 2007, **62**, 630–632.
- 27 S. Abid, A. Lekchiri, H. Mekhfi, A. Ziyat, A. Legssyer, M. Aziz and M. Bnouham, *J. Diabetes*, 2014, **6**, 351–359.
- 28 M. Bnouham, W. Benalla, S. Bellahcen, Z. Hakkou, A. Ziyat, H. Mekhfi, M. Aziz and A. Legssyer, *J. Diabetes*, 2012, **4**, 307–313.
- 29 V. Täckholm, *Ancient Egypt, Landscape, Flora and Agriculture*, 1976.
- 30 C. G. Michel, D. I. Nesseem and M. F. Ismail, *J. Ethnopharmacol.*, 2011, **133**, 53–62.
- 31 R. Avizeh, H. Najafzadeh, M. P. Borujeni and M. Mirzaee, *Int. J. Appl. Res. Vet. Med.*, 2010, **8**, 109–113.
- 32 A. Bozicevic, M. De Mieri, A. Di Benedetto, F. Gafner and M. Hamburger, *Phytochemistry*, 2017, **138**, 134–144.
- 33 N. M. I. Elnagar and B. M. Modawi, *Orient. J. Chem.*, 2016, **32**, 895–901.
- 34 A. Said, A. Huefner, E. A. A. Tabl and G. Fawzy, *J. Biol.*, 2011, **70**, 39–43.
- 35 J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski and G. Los, *Mol. Cancer Ther.*, 2007, **6**, 3314–3322.
- 36 R. Wang, L. Tong, C. Y. Liu and C. Guo, *J. Asian Nat. Prod. Res.*, 2019, **21**, 1215–1220.
- 37 B. Feng, Y. Pei, H. Hua, T. Wang and Y. Zhang, *Pharm. Biol.*, 2003, **41**, 59–61.
- 38 M. Taniguchi and K. Baba, *Phytochemistry*, 1996, **42**, 1447–1453.
- 39 P. Gürbüz and Ş. D. Doğan, *Biochem. Syst. Ecol.*, 2017, **74**, 57–59.
- 40 K. Yasukawa, H. Sekine and M. Takido, *Phytochemistry*, 1989, **28**, 2215–2216.
- 41 G. E. D. Hussein Mahran, K. W. Glombitza, Y. W. Mirhom, R. Hartmann and C. G. Michel, *Planta Med.*, 1996, **62**, 163–165.
- 42 H. Van Tilbeurgh, M.-P. Egloff, C. Martinez, N. Rugani, R. Verger and C. Cambillau, *Nature*, 1993, **362**, 814–820.
- 43 H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov and P. E. Bourne, *Nucleic Acids Res.*, 2000, **28**, 235–242.



- 44 G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju and W. Sherman, *J. Comput.-Aided Mol. Des.*, 2013, **27**, 221–234.
- 45 T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard and J. L. Banks, *J. Med. Chem.*, 2004, **47**, 1750–1759.
- 46 Y. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang and S. H. Bryant, *Nucleic Acids Res.*, 2009, **37**, W623–W633.
- 47 D. Shivakumar, J. Williams, Y. Wu, W. Damm, J. Shelley and W. Sherman, *J. Chem. Theory Comput.*, 2010, **6**, 1509–1519.
- 48 S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw and R. A. Friesner, *J. Comput.-Aided Mol. Des.*, 2006, **20**, 647–671.
- 49 R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin and D. T. Mainz, *J. Med. Chem.*, 2006, **49**, 6177–6196.
- 50 G. K. Veeramachaneni, K. K. Raj, L. M. Chalasani, S. K. Annamraju, B. Js and V. Talluri, *Bioinformation*, 2015, **11**, 535–542.
- 51 P. Slanc, B. Doljak, S. Kreft, M. Lunder, D. Janeš and B. Štrukelj, *Phytother. Res.*, 2009, **23**, 874–877.
- 52 C. A. Lipinski, *Drug Discovery Today: Technol.*, 2004, **1**, 337–341.
- 53 D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, *J. Med. Chem.*, 2002, **45**, 2615–2623.

